News und Analysen
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Agilent Technologies Inc. (NYSE: A) today announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or
Agilent Announces Thought Leader Award to Professor Jennifer Field
Agilent Technologies Inc. (NYSE: A) today announced that Jennifer Field, an influential researcher in environmental analysis, has been selected to receive a prestigious Agilent Thought Leader
Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is forging a path to better outcomes for those impacted by Alzheimer’s Disease and
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2
DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Humana Announces Four New Sponsorships of Leading U.S. Pickleball Organizations to Inspire and Promote Active and Healthy Lifestyles for All Ages, With a Special Focus on Seniors
In recognition of pickleball’s rapidly growing popularity in the U.S., the increasing need for court space across the country, and the sport’s life-changing benefits both on and off the courts
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
Pfizer Inc. (NYSE: PFE) will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
QuidelOrtho Reports Third Quarter 2023 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
Pfizer Reports Third-Quarter 2023 Results
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2023. The company reaffirms its 2023 revenue guidance(4) range of $58.0 to $61.0 billion and its outlook for Adjusted(3)
Humana and Greater Good Health Expand Access to Primary Care in Montana with Opening of Senior-focused Primary Care Clinics
Humana, a leading health and well-being company, and Greater Good Health, a healthcare organization expanding access to primary care for seniors through a nurse practitioner-led value-based care
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023.
Third Quarter 2023 Financial Highlights:
-
Revenue grew 27% versus the same
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of
Agilent to Announce Fourth-Quarter Fiscal Year 2023 Financial Results Nov. 20
Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2023 after the stock market closes on Monday, Nov. 20. In addition, the company will host a
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent
Agilent’s Net-Zero Emissions Targets Approved by the Science Based Targets Initiative
Agilent Technologies Inc. (NYSE: A) today announced the company’s near and long-term targets for reaching net-zero greenhouse gas emissions have been approved by the Science Based Targets
Sartorius Stedim Biotech SA: Nine-month results 2023 of Sartorius Stedim Biotech
Humana’s Medicare Advantage Footprint in New Jersey Complete
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its health plans to Middlesex County, widening the company’s Medicare Advantage footprint to 100% of the state.
For the
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech pre-announces preliminary 9-month results and lowers forecast for 2023
QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and